02Apr 2023
Vedolizumab for the Treatment of Chronic Pouchitis

Vedolizumab for the Treatment of Chronic Pouchitis

This phase 4 randomized trial evaluated the effectiveness of vedolizumab in adult patients who developed chronic pouchitis after undergoing ileal pouch–anal anastomosis (IPAA) for ulcerative colitis. Patients were assigned to receive vedolizumab or a placebo and were evaluated based on different efficacy endpoints. Results showed that vedolizumab was more effective than placebo in inducing remission in patients with chronic pouchitis after IPAA for ulcerative colitis. The incidence of mPDAI-defined remission at week 14 was 31% with vedolizumab and 10% with placebo. Serious adverse events occurred in 6% of patients in the vedolizumab group and 8% in the placebo group.

  • #family health

Like

Save

Share